Novavax COVID-19 Vaccine, Adjuvanted indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. / CBS News. Stock is most profitable biotech short since pandemic high: S3, Company valuation topped $20 billion amid 2021s biotech mania. You can review and change the way we collect information below. AAAS is a partner of HINARI, AGORA, OARE, CHORUS, CLOCKSS, CrossRef and COUNTER. It found a new life as it collected $2 billion to develop a vaccine, first from an international organization that supports vaccinemaking and then from the U.S. government. The US Food and Drug Administration on Wednesday authorized Novavaxs Covid-19 vaccine for emergency use in adults. The Phase 2 dose-confirmation trial will be conducted in two parts. Anything we can do to get people to be able to accept these potentially lifesaving medical products is something that we feel we are compelled to do.. So, you Topline. You will be subject to the destination website's privacy policy when you follow the link. Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights. Waning interest in Covid-19 vaccines has left a long-standing drug developer, Novavax Inc., struggling to stay afloat and handed short sellers a windfall. Last updated by Melisa Puckey, BPharm on Oct 19, 2022. "I am excited to be joining Novavax at this important time in the company's history," said John C. Jacobs, President and Chief Executive Officer, Novavax. At the time, most U.S. adults had received at least one COVID-19 vaccine dose. Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data. The maker of the only traditional COVID-19 vaccine still widely available in the United States is raising doubts about its ability to stay FDA Novavax Reports Fourth Quarter and Full Year 2022 Financial Novavax did not present any on data on the shot's effectiveness against the variant at the FDA committee meeting in June. To access the replay by telephone, dial (877) 344-7529 (Domestic) or (412) 317-0088 (International) and use passcode 1137418. This is a case study of perseverance, Bruce Gellin, chief of global public health strategy at the Rockefeller Foundation, said after the vote. If the Food and Drug Administration (FDA) accepts the group's recommendation and Centers for Disease ET. To maximize our opportunities and mitigate the significant risks and uncertainties of the COVID-19 market, our goal is to reduce spend, extend our cash runway and operate efficiently to best position the company to deliver long-term growth. Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. In this photo illustration the Food and Drug Administration (FDA) and Novavax logos are seen behind a medical syringe and vials. Shares of Novavax fell more than 25% in after-hours trading Tuesday, following a dismal fourth quarter earnings report and a warning from the Covid The effectiveness of Covid vaccines against mild illness has slipped substantially as the virus as evolved, though they still generally protect against severe disease. Please visit novavax.com and LinkedIn for more information. Its also the most profitable short among biotechs since the stock hit a peak at the height of the outbreak, according to Matthew Unterman, a director with S3. Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S. First published on July 13, 2022 / 4:18 PM. The Novavax COVID-19 Vaccine (NVXCoV2373) is engineered from the genetic sequence of SARSCoV2, and uses recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein. Novavax has otherwise touted its use of older vaccine 2 billion. The shots consist of 5 micrograms of the spike copy and 50 micrograms of the adjuvant. The dial-in numbers for the conference call are (833) 974-2381 (Domestic) or (412) 317-5774 (International). The thumbs up from the FDA advisers likely means the agency will allow the company to enter the U.S. market, as FDA usually follows its advisers lead. The Novavax shot also has low reactogenicitymeaning immediate side effects, from painful arms to malaise. We believe that if we succeed in executing against these priorities, we will position the company well for long-term success. Myocarditis is an inflammation of the heart muscle and pericarditis is inflammation of the outer lining of the heart. Saving Lives, Protecting People, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, FAQs for the Interim Clinical Considerations, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Considerations for Planning School-Located Vaccination Clinics, How Schools and ECE Programs Can Support Vaccination, Customizable Content for Vaccination Clinics, Best Practices for Schools and ECE Programs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services. The Food and Drug Administration advisory committee recommends the agency authorize another COVID-19 vaccine in the hopes it might entice more people to On August 19, 2022, the Food and Drug Administration (FDA) authorized the Novavax COVID-19 Vaccine, Adjuvanted for emergency use in individuals ages 12 and older. Novavax creates transformational vaccines that help address some of the worlds most pressing infectious diseases. The Novavax shot is based on more conventional protein technology used for decades in hepatitis B and HPV vaccines, while Pfizer and Moderna are the first FDA approved vaccines to use mRNA. The relevance of a particular drug interaction to a specific individual is difficult to determine. SAGE recommends the use of the Novavax (NVX-CoV2373) vaccine as 2 doses (0.5 ml) given intramuscularly. The recipients health condition or recommendations for vaccination may change from one visit to the next. Waning interest in Covid-19 vaccines has left a long-standing drug developer, Novavax Inc., struggling to stay afloat and handed short sellers A new investigational treatment for COVID-19: The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Data is a real-time snapshot *Data is delayed at least 15 minutes. 13,14 Accordingly, development of effective and safe vaccines that provide Join other passionately curious people who are bringing innovative vaccines to the world. COVID vaccine maker Novavax notes substantial doubts about ET on February 28, 2023 until 11:59 p.m. A key committee of advisers to the U.S. Food and Drug Administration (FDA) today recommended nearly unanimously that the agency grant an emergency The maker of the only traditional COVID-19 vaccine still widely available in the United States is raising doubts about its ability to stay in business. COVID vaccine With Novavax's unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax's Matrix-M adjuvant enhances and broadens the immune response. Most reactions were mild or moderate, but reactogenicity was greater following the second dose. Before sharing sensitive information, make sure you're on a federal government site. WebOn February 1, 2022, FDA received a request from Novavax (the Sponsor) for emergency use authorization (EUA) of the Novavax COVID-19 Vaccine. WebNovavax COVID-19 Vaccine, Adjuvanted is available under emergency use authorization (EUA) to prevent COVID-19 in individuals 12 years of age and older. The immune system responds to these copies of the spike, which prepares the human body to attack the actual virus. Approved vaccines for shingles, hepatitis B, and influenza use similar protein-based technology. The Centers for Disease Control and Prevention still needs to sign off on Novavax's vaccine before pharmacies and other health-care providers can start administering shots. How To Get Novavax, the Recently Authorized COVID-19 Covid-19 vaccine maker Novavax raised doubts Tuesday about its ability to continue its business, announcing plans to cut All Rights Reserved. The Novavax COVID-19 Vaccine, Adjuvanted has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for Like the mRNA vaccine makers, Novavax says it is also studying a version of its shots redesigned to target the BA.4 and BA.5 subvariants of Omicron now dominant across the country. The relevance of a particular drug interaction to a specific individual is difficult to determine. Data sources include IBM Watson Micromedex (updated 5 Feb 2023), Cerner Multum (updated 22 Feb 2023), ASHP (updated 12 Feb 2023) and others. The company stated it believes it has enough capital to run for another year, but the forecast is of low confidence, in part because the Biden Administration is expected to stop buying Covid vaccines and distributing them to Americans for free at some point this year. "What really took the longest time, however, wasn't the manufacturing of the product. With nearly 22% of the nation yet to receive a single COVID-19 vaccine dose, federal vaccine advisers today recommended that the Novavax COVID-19 vaccine be approved under an emergency use authorization (EUA). 2 It is the first protein-based COVID-19 vaccine authorized in the U.S. zoranm / Getty Images. Dosage form: intramuscular injection Our Research: COVID-19 | Novavax - New Era of Revolutionary Pfizer and Moderna's vaccines use mRNA, a molecule encoded with genetic instructions, to tell human cells to produce copies of a virus particle called the spike protein. The vaccine is authorized for emergency use to provide: Novavax COVID-19 Vaccine, Adjuvanted contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. The accompanying condensed consolidated financial statements have been prepared assuming Novavax will continue as a going concern. Novavax Novavax presented data at an FDA committee meeting in late June demonstrating that a third dose of its vaccine produced a strong immune response against omicron and its subvariants. Copyright 2023 CBS Interactive Inc. All rights reserved. Young men have had the highest rates of myocarditis or pericarditis after receiving mRNA vaccines. The Novavax COVID-19 vaccine has been authorized for emergency use by the U.S. Food and Drug Administration (FDA), the agency announced Wednesday. Novavax, in use in the U.S. since mid-2022, warned it may not survive in its latest earnings report, released after the market closed on Tuesday, CNN reported. Novavax won approval in the European Union several months before its U.S. rollout, but it was still well behind competitors, and its international campaign has not been enough to overcome a slow rate of uptake in the United States. ", Fourth Quarter 2022 and Recent Highlights, COVID-19 Vaccine Orders and Plans for the 2023 Fall Vaccination Season, COVID-19 Vaccine Clinical Development Program and Expanded Authorizations, COVID-19-Influenza Combination (CIC) Vaccine Candidate Clinical Development, Fourth Quarter and Full Year 2022 Financial Results. The Food and Drug Administration has authorized Novavax's two-dose vaccine for adults ages 18 and over, the fourth Covid shot to get emergency approval in the U.S. since the pandemic began. Alex Murdaugh sentenced to life in prison for murders of wife and son, Biden had cancerous skin lesion removed last month, doctor says, White supremacist and Holocaust denier Nick Fuentes kicked out of CPAC, Tom Sizemore, actor known for "Saving Private Ryan" and "Heat," dies at 61, Biden team readies new advisory panel ahead of expected reelection bid, At least 10 dead after winter storm slams South, Midwest, House Democrats unhappy with White House handling of D.C.'s new criminal code. We comply with the HONcode standard for trustworthy health information. Thank you for taking the time to confirm your preferences. Cookies used to make website functionality more relevant to you. You can review and change the way we collect information below. Centers for Disease Control and Prevention. Our business is subject to substantial risks and uncertainties, including those referenced above. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. Two doses of the Novavax vaccine were 90% effective at preventing illness from Covid across the board and 100% effective at preventing severe illness, according to clinical trial data from the U.S. and Mexico. Tracking Covid-19. With Novavax, each vaccine is spaced three weeks apart. Primary and secondary objectives of the study are to assess the safety, tolerability, and immune responses to various formulations of the CIC and influenza vaccine candidates. Novavax COVID-19 Vaccine, Adjuvanted is available under emergency use authorization (EUA) to prevent COVID-19 in individuals 12 years of age and older. The Novavax COVID-19 vaccine has been authorized for emergency use by the U.S. Food and Drug Administration (FDA), the agency announced Wednesday. New Era of Revolutionary Vaccines EUA in the USA | Novavax Saving Lives, Protecting People, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, FAQs for the Interim Clinical Considerations, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Considerations for Planning School-Located Vaccination Clinics, How Schools and ECE Programs Can Support Vaccination, Customizable Content for Vaccination Clinics, Best Practices for Schools and ECE Programs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services. "We're in the process of assessing the global footprint of Novavax, rationalizing our supply chain, rationalizing the portfolio and rationalizing the company structure and our infrastructure," Jacobs told Reuters. Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine. Credit: Unsplash/CC0 Public Domain. Adverse events that occur in a recipient after COVID-19 vaccination are required to be reported to the Vaccine Adverse Event Reporting System (VAERS). Coronavirus Disease 2019 (COVID-19), Recalls, Market Withdrawals and Safety Alerts, COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders, Fact Sheet for Healthcare Providers Administering Vaccine, HOJA INFORMATIVA PARA RECEPTORES Y PROVEEDORES DE CUIDADO, FACT SHEET PARA SA MGA TATANGGAP AT MGA TAGAPAG-ALAGA, T THNG TIN CHO NGI NHN V NHNG NGI CHM SC. People who experience chest pain, shortness of breath and feelings of a fluttering or pounding heart should immediately seek medical attention, according to the FDA. The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2 to 8C, enabling the use of existing vaccine supply and cold chain channels. Rubio Proposes Permanent Daylight Saving BillHeres Why Its Likely To Fail, Again, Florida Senators Ask Biden To Allow Novak Djokovic To Play Miami Open Despite Covid Restrictions, These Major CompaniesFrom Snap To Instacart Are All Using ChatGPT, DeSantis Disney District Board Appointee Has A History Of Homophobic Comments, Biden Has Skin Cancer Cell Removed Following Same Operation On First Lady, Big Tech's $200 Billion Surge Leads Stock Market RallyBut Rate-Fueled Optimism May Be Fleeting, Marjorie Taylor Greene Ramps Up Anti-Ukraine Rhetoric: Zelensky Wants Our Sons And Daughters To Go Die, CPAC Chair Matt Schlapp Says Bigot Nick Fuentes Was Booted From Event Over Antisemitic Comments, Here Are 20 Major Cities Where Home Prices Are Dropping The Most, All Covid Origin TheoriesIncluding Lab LeakOn The Table, WHO Director Says, Murdaugh Jury Needed 45 Minutes For Unanimous Verdict: Evidence Was Clear, Biden Sides With Republicans On A Bill To Reverse D.C. Criminal Justice ReformsHeres Why. Find information and resources for each of the available Novavax COVID-19 Vaccines. Select one or more newsletters to continue. They help us to know which pages are the most and least popular and see how visitors move around the site. FDA officials flagged four cases of myocarditis and pericarditis from Novavax's clinical trial in young men ages 16 to 28. WebAmpoules containing the COVID-19 vaccine Nuvaxovid from the manufacturer Novavax sit on a table at a vaccination center on April 1, 2022, in Quedlinburg, Germany. Novavax, on the other hand, includes the proteins in its vaccine. Sign up for free newsletters and get more CNBC delivered to your inbox. Novavax Stock Plunges 25% As Vaccine Maker Has Substantial But manufacturing issues have hampered Novavaxs effort and sidelined its would-be U.S. vaccinemaking facilities. FDA requires vaccination providers to report vaccine administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration of COVID-19 vaccine under an EUA. The trial assessed two doses (5 and 25 g), each with 50 g of MatrixM. When FDAs advisers gave a green light to the Moderna and Pfizer vaccines in late 2020, the agency acted quickly to issue EUAs for those vaccines. Novavaxs vaccine was the fourth to reach the U.S. market, entering U.S. arms more than a year after Pfizer, Moderna and Johnson & Johnson. COVID At their June 7 meeting, FDA officials had said the agency was still in the midst of vetting the company's process for manufacturing and checking the quality of shots an issue that the company's executives acknowledged was one of the biggest obstacles to completing its submission to the regulator. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Thank you for taking the time to confirm your preferences. Novavax is not responsible for the privacy policy of any third-party websites. Novavax raised doubts about its future Tuesday as concerns grow about whether the Covid vaccine [+] maker will ever get a significant foothold in the United States. Statements herein relating to the future of Novavax, its near term priorities including delivering an updated vaccine for the 2023 fall vaccination season, streamlining its investment and organizational structure and building value for Novavax from its technology platform and Matrix-M adjuvant, its operating plans, objectives and prospects, including Novavax's ability to continue as a going concern within one year after the issuance date of the financial statements for the year ended December 31, 2022, its anticipated strategic plan, its future financial or business performance, conditions or strategies, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, and a bivalent or monovalent Omicron-based / original strain based vaccine, the CIC investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future and pending regulatory filings and actions and additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents and as a booster, are forward-looking statements. In addition, the company struggled mightily to show it could make the vaccine consistently. But now it has a bigger problem: farmers are revolting against restrictions on how they repair complex equipment. FDA authorization of Novavax's vaccine was delayed for weeks as the agency reviewed changes to the company's manufacturing process. The company has said it plans to pursue an authorization for its current vaccine to be used as a booster shot as well. This U.S. COVID-19 vaccine maker faces uncertain future FDA authorizes Novavax Covid vaccine for adults - CNBC You are encouraged to read our filings with the SEC, available at www.sec.govand www.novavax.com, for a discussion of these and other risks and uncertainties. maker will ever get a significant foothold in the United States. FDA authorization of Novavax's vaccines comes as the U.S. is preparing to updated Covid shots to target the omicron BA.4 and BA.5 variants to increase protection against the virus. Novavax's shots have received FDA authorization at a time when nearly 77% of adults ages 18 and over are already fully vaccinated. The Phase 1/2 randomized, observer-blinded, placebo-controlled trial of NVXCoV2373 commenced in May 2020 and included 131 healthy volunteers aged 18-59 years at two Australian sites (Melbourne and Brisbane). Complete and submit reports to VAERS online. But 21 of the 22 advisers concluded any risk posed by heart inflammation was outweighed by the benefits of a vaccine that showed 90.4% efficacy against early strains of SARS-CoV-2 in a trial involving 30,000 people in the United States and Mexico. Novavax has otherwise touted its use of older vaccine technology for its COVID shot as a good alternative to the country's stable of effective vaccines because it has been administered with fewer side effects during trials than the Pfizer or Moderna shots. Early in their development, studies of those two vaccines included testing on a controversial cell line linked to an abortion in the 1970s that is widely used in medical research though neither shot ultimately uses any fetal tissue in manufacturing their vaccines. Novavax COVID-19 Vaccine FDA Approval Status - Drugs.com doses per year at full capacity. Dr. Peter Marks, a senior FDA official, said Novavax's vaccine would potentially appeal to unvaccinated people who would prefer a shot that is not based on the messenger RNA technology used by Pfizer and Moderna. We need to provide options to reduce excuses, Martha Dawson, president of the National Black Nurses Association, told the advisers. The fact sheets authorized for Novavax's shots will ultimately include the warning, the FDA said. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant, Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster, U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults, U.S. Centers for Disease Control and Prevention Expands Recommendation for Novavax COVID-19 Vaccine, Adjuvanted to Adolescents Aged 12 Through 17, U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17, Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older, Novavax Announces Initiation of Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years, U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over, FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older, Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial, Health Canada Authorizes Novavax COVID-19 Vaccine, Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial, New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine, Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine, Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine, Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies, Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study, World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine, Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine, Novavax Statement on PREVENT-19 Phase 3 Clinical Trial Results Publication in the New England Journal of Medicine, Novavax Statement on Omicron Variant Response, Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization, Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization, Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand, Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia, Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency, Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia, Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom.